Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-11-15
2008-08-19
Crane, L. E. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S026230, C536S026260, C536S026700, C536S027200
Reexamination Certificate
active
07414031
ABSTRACT:
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.
REFERENCES:
patent: 4107288 (1978-08-01), Oppenheim et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5597691 (1997-01-01), Houghton et al.
patent: 5738985 (1998-04-01), Miles et al.
patent: 5739002 (1998-04-01), De Francesco et al.
patent: 5759795 (1998-06-01), Jubin
patent: 5861267 (1999-01-01), Su
patent: 6030785 (2000-02-01), Katze et al.
patent: 6228576 (2001-05-01), Delvecchio
patent: 6777395 (2004-08-01), Bhat et al.
patent: 7105499 (2006-09-01), Carroll et al.
patent: 7125855 (2006-10-01), Bhat et al.
patent: 7202224 (2007-04-01), Eldrup et al.
patent: 2005/0090463 (2005-04-01), Roberts et al.
patent: 2006/0079468 (2006-04-01), Roberts et al.
patent: WO 97/12033 (1997-04-01), None
patent: WO 01/90121 (2001-11-01), None
patent: WO 02/18404 (2002-03-01), None
patent: WO 02/057287 (2002-07-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 03/061385 (2003-07-01), None
patent: WO 03/061576 (2003-07-01), None
patent: WO 2004/007512 (2004-01-01), None
patent: WO 2004/028481 (2004-04-01), None
patent: WO 2005/021568 (2005-03-01), None
patent: WO 2005/042556 (2005-05-01), None
Cooperwood, J. S., et al., “Nucleoside and Nucleotide prodrugs” in Ed(s) Chu, C. K. Recent Advances in Nucleosides 2002, 92-147.
Ding, et al. “Synthesis of 2′-beta-C-methyl toyocamycin and sangivamycin analogues as potential HCV inhibitors” Bioorganic & Medicinal Chemistry Letters, 15(3):725-727, Feb. 2005.
Ferrari, et al., “Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed inEscherichia coli” J. Viro., 1999, 73, 1649-54.
Hinshaw, et al. “Pyrrolopyrimidine nucleosides. IV. Synthesis of certain 4, 5-disubstituted-7-(beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines related to the pyrrolo[2,3-d] pyrimidine nucleoside antibiotics” J. of Heterocyclic Chemistry 1969, 6(2):215-221.
Hinshaw, et al. “Pyrrolopyrimidine nucleosides. Part X. Synthesis of certain 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines related to toyocamycin and sangivamycin” J. of the Chemical Society, Perkin Transactions: Organic and Bio-Organic Chemistry 1975 13, 1248-53.
Hutchinson, D.W. (Ed. Leroy B. Townsend) “The Synthesis, Reaction and Properties of Nucleoside Mono-, Di-, Tri-, and Tetraphosphates and Nucleosides with Changes in the Phosphoryl Residue” Chemistry of Nucleosides and Nucleotides, Plenum Press, (1991) 2.
Ishii, et al., “Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding.” Hepatology, 1999, 29, 1227-35.
Lohmann, et al., “Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.” Science, 1999, 285, 110-13.
Lohmann, et al., “Selective Stimulation of Hepatitis C Virus and Pestivirus NS5B RNA Polymerase Activity by GTP.” J. Bio. Chem., 1999, 274, 10807-15.
Mandal, S.B., et al., “Stereospecific C-β-glycosidation and synthesis of 4,7-anhydro-5,6-isopropylidene-4(S), 5(S), 6(R), 7(R)-tetrahydroxyoxocan-2-one” Synth. Commun., 1993, 9, 1239.
Meier, C., “Pro-Nucleotides—recent advances in the design of efficient tools for the delivery of biologically active nucleoside monophosphates” Synlett 1998, 3, 233-42.
Ning, J., et al., “Syntheses and reactions of 5-O-acetyl-1,2-anhydro-3-O-benzyl-alpha-D-ribofuranose and beta-D-lyxofuranose, 5-O-acetyl-1,2-anhydro-3,6-di-O-benzyl- and 1,2-anhydro-5,6-di-O-benzoyl-3-O-benzyl-beta-D-mannofuranose, and 6-O-acetyl-1,2-anhydro-3,4-di-O-benzyl-alpha-D-glucopyranose and—beta-D-talopyranose,” Carbohydr. Res., 2001, 330, 165-75.
Saunders and Raybuck, “Inosine Monophosphate Dehydrogenase: Consideration of Structure, Kinetics and Therapeutic Potential.” Ann. Rep. Med. Chem., 2000, 35, 201-10.
Seela, et al., “7-substituted-7-deaza-2′-deoxyadenosines and 8-aza-7-deaza-2′-deoxyadenosines: fluorescence of DNA-base analogues induced by the 7-alkynyl side chain” Helvetica Chimica Acta, 2000 83(5), 910-927.
Wagner, C., et al., “Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides.” Medicinal Research Reviews 2000, 20(6), 417-451.
Witty, D.R., et al., “Ring contraction of 2-o-trifluoromethanesulphonates of α-hydroxy-γ-lactones to oxetane carboxylic esters.” Tet. Lett., 1990, 31, 4787.
Yamashita, et al., “RNA-dependent RNA Polymerase Activity of the Soluble Recombinant Hepatitis C Virus NS5B Protein Truncated at the C-terminal Region,” J. Bio. Chem., 1998, 273, 15479-86.
Zemlicka, J., et al., “Lipophilic phosphoramidates as antiviral pronucleotides.” Biochimica et Biophysica Acta 2002, 158(2-3), 276-286.
Dyatkina Natalia B.
Keicher Jesse D.
Roberts Christopher D.
Crane L. E.
Foley & Lardner LLP
Genelabs Technologies, Inc.
Yang Junrui
LandOfFree
5-nitro-nucleoside compounds for treating viral infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-nitro-nucleoside compounds for treating viral infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-nitro-nucleoside compounds for treating viral infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3995109